Taevas
MexicoPharmaceuticals
Product Registration
Product Registration for Pharmaceuticals in Mexico
Taevas Global guides pharmaceutical manufacturers through every stage of COFEPRIS product registration, turning complex regulatory requirements into a clear, executable path to the Mexican market. Whether you are launching a new molecule or expanding an e
Market
Mexico
Industry
Pharmaceuticals
Service
Product Registration
Regulator
COFEPRIS (Comision Federal para la Proteccion contra Riesgos Sanitarios)
Timeline
12-18 months (standard dossier review)
What We Deliver
Six Pillars of Mexico Pharmaceuticals Intelligence
Our six interconnected pillars give pharmaceutical manufacturers the regulatory clarity, market insight, and strategic positioning needed to register and commercialize products successfully in Mexico.
01
Regulatory Pathway Mapping
We identify the precise COFEPRIS registration route for your product category, whether new chemical entity, generic, biologic, or OTC. Our team analyzes applicable NOM standards, FEUM requirements, and any fast-track or expedited review options available. This prevents costly pathway misclassification before a single document is submitted.
Classification under Ley General de Salud and its Reglamento de Insumos para la Salud
Identification of applicable NOMs and FEUM monographs
Assessment of bioequivalence and bioavailability study requirements
How It Works
From Brief to Board-Ready Intelligence
Our four-step engagement moves from initial scoping through deep regulatory research, structured dossier development, and final delivery of a submission-ready package with strategic recommendations.
Step 1 · Day 1-2
Discovery and Scoping
We conduct a structured intake session to understand your product profile, target indication, manufacturing site, and commercial goals. This defines the exact COFEPRIS registration route, identifies data gaps, and sets a realistic timeline and budget. You receive a written scope confirmation before any work begins.
Taevas Approach
During discovery we review your existing technical documentation, confirm product classification under Mexican law, assess whether foreign approvals (FDA, EMA) can be leveraged for an expedited review, and identify any bioequivalence or clinical bridging study requirements. The output is a detailed project charter with milestones, responsibilities, and risk flags.
Market Snapshot
Mexico Pharmaceuticals Market at a Glance
$0B+
Estimated Annual Market Value (USD)
0%
Projected Annual Market Growth Rate
0+
Licensed Pharmaceutical Manufacturers
0K+
Active Sanitary Registrations (COFEPRIS)
Latin America's Second-Largest Pharma Market
Mexico is the second-largest pharmaceutical market in Latin America, driven by a population of over 130 million, expanding public health coverage under IMSS and ISSSTE, and growing middle-class demand for branded and generic medicines. The market encompasses both a large institutional public sector and a dynamic private retail channel, requiring tailored registration and commercialization strategies for each segment.
COFEPRIS Modernization and Convergence
COFEPRIS has progressively aligned its review processes with international standards, including participation in the Pan American Network for Drug Regulatory Harmonization (PANDRH) and recognition of foreign regulatory decisions from stringent authorities such as the FDA and EMA under its expedited review pathway. This convergence reduces duplicative testing requirements for manufacturers with existing approvals in reference markets, but navigating the specifics still requires local expertise.
Generics and Biosimilars Growth Opportunity
Generic medicines account for approximately 70 percent of units sold in Mexico, and the biosimilars segment is expanding rapidly following the establishment of a formal regulatory pathway under COFEPRIS guidelines and the Farmacopea de los Estados Unidos Mexicanos. Companies with off-patent molecules or biosimilar pipelines have a significant growth opportunity, particularly in the public procurement channel where price competition is intense.
Digital Health and Supply Chain Investment
Mexico's pharmaceutical sector is investing in serialization and traceability infrastructure following regulatory requirements for anti-counterfeiting measures, creating new compliance obligations for registered products. The government's push to increase domestic production capacity and reduce import dependency is also reshaping the landscape for foreign manufacturers considering local manufacturing partnerships or technology transfer arrangements.
What's Included
Everything in Your Report
Every Taevas Global Product Registration engagement for Mexico Pharmaceuticals delivers eight structured outputs that take you from regulatory mapping to submission-ready documentation and market entry strategy.
Regulatory Pathway Assessment Report
A written analysis of the applicable COFEPRIS registration route for your product, including classification rationale, applicable NOMs, and identification of any expedited review eligibility based on foreign regulatory approvals.
Dossier Gap Analysis
A module-by-module review of your existing technical documentation against current COFEPRIS requirements, with a prioritized remediation plan, effort estimates, and clear identification of submission blockers.
Competitive Registration Landscape
A structured overview of currently registered competing products in your therapeutic category, including originator and generic holders, patent linkage status, and pricing benchmarks across public and private channels.
Compliance and Legal Framework Summary
A plain-language guide to the Mexican legal and regulatory framework governing your product type, covering the Ley General de Salud, Reglamento de Insumos para la Salud, relevant NOMs, and post-approval pharmacovigilance obligations.
In-Country Partner Shortlist
A vetted list of qualified Mexican Titulares del Registro, contract manufacturers, and distribution partners, with profiles, capabilities, and recommended due diligence questions for your selection process.
Submission-Ready Dossier Package
A fully assembled, COFEPRIS-formatted dossier including all administrative, quality, safety, and efficacy modules, Spanish-language expert reports, and NOM-072-SSA1-compliant labeling ready for SIGES electronic submission.
Post-Approval Compliance Roadmap
A forward-looking compliance calendar covering renewal deadlines, variation filing obligations, pharmacovigilance system requirements under NOM-220-SSA1, and a step-by-step guide to Cuadro Basico formulary inclusion.
Market Entry Strategy Brief
A board-ready strategic summary integrating regulatory status, competitive positioning, channel strategy recommendations, and key milestones for commercial launch in Mexico's public and private pharmaceutical markets.
Who This Is For
Built for These Situations
Market Entry
Foreign Manufacturer Entering Mexico for the First Time
Your company has an approved product in the US, EU, or another reference market and is now targeting Mexico as the next growth market. You need to understand COFEPRIS requirements, appoint a local Titular del Registro, and build a compliant dossier without diverting your internal regulatory team from existing markets. The process is unfamiliar, timelines are unclear, and the cost of a deficiency letter or wrong pathway selection is high.
Outcome
A clear registration roadmap, a vetted local partner, and a submission-ready dossier that minimizes review delays and gets your product to Mexican patients faster.
Next Steps
After Product Registration, Most Clients Move To
FAQ
Common Questions
Get Started
Ready to Map Your Mexico Opportunity?
Speak with a Taevas Global pharmaceutical regulatory specialist today to understand your COFEPRIS registration pathway, timeline, and market entry options. We typically respond to all consultation requests within one business day.
COFEPRIS pathway confirmed within 48 hours of intake
Full dossier gap analysis delivered in under three weeks
Vetted Mexican Titular del Registro introductions included
End-to-end support from submission through post-approval compliance